ImmunityBio (NASDAQ:IBRX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

ImmunityBio (NASDAQ:IBRX) announced its quarterly earnings data on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The firm had revenue of $38.29 million for the quarter.

ImmunityBio Trading Up 1.0%

IBRX opened at $8.70 on Monday. The business’s 50 day moving average is $4.48 and its 200-day moving average is $3.12. The stock has a market cap of $8.57 billion, a PE ratio of -21.22 and a beta of 0.14. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $9.25.

Wall Street Analyst Weigh In

IBRX has been the subject of several research reports. HC Wainwright lifted their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, January 26th. D. Boral Capital reissued a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. BTIG Research increased their price target on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Piper Sandler boosted their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.80.

Insider Buying and Selling

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barry J. Simon sold 151,967 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the transaction, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 226,967 shares of company stock valued at $1,531,912 over the last three months. Corporate insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC raised its position in shares of ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after buying an additional 29,297 shares in the last quarter. Creative Planning increased its stake in shares of ImmunityBio by 9.2% during the second quarter. Creative Planning now owns 62,028 shares of the company’s stock valued at $164,000 after acquiring an additional 5,231 shares during the period. Cetera Investment Advisers raised its holdings in ImmunityBio by 56.9% during the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock worth $49,000 after purchasing an additional 6,731 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in ImmunityBio by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 1,071,736 shares of the company’s stock worth $2,829,000 after purchasing an additional 52,782 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in ImmunityBio by 11.8% in the second quarter. Legal & General Group Plc now owns 205,478 shares of the company’s stock worth $542,000 after purchasing an additional 21,715 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.